Healthcare / Medical DevicesKuala Lumpur
$0.78
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $21.7M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$312M
P/E
4.1x
↓EV/EBITDA
8.4x
↓ROE
18.5%
↑Gross Margin
29.0%
↓Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+23.7%
FCF CAGR
—
FCF margin
-5.7%
FCF / Net income
-0.53x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $201.6M · net income $21.9M · FCF $-11.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $201.6M | $201.6M | $183.2M | $150.3M | $106.6M |
| Net Income | $21.9M | $21.9M | $20.4M | $20.7M | $13.1M |
| EBITDA | $32.9M | $32.9M | $27.9M | $27.0M | $18.2M |
| EPS | — | — | 0.05 | 0.05 | 0.03 |
| Gross Margin | 29.0% | 29.0% | 24.8% | 27.3% | 27.9% |
| Operating Margin | 15.6% | 15.6% | 15.1% | 16.3% | 18.5% |
| Net Margin | 10.9% | 10.9% | 11.1% | 13.8% | 12.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.43 | 0.64 | 1.40 |
| Current Ratio | 2.19 | 2.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-11.6M | $-11.6M | $30.2M | $21.7M | $2.6M |
| Returns | |||||
| ROE | 18.5% | 18.5% | 42.7% | 52.0% | 52.0% |
| Valuation | |||||
| P/E | 4.11 | 4.11 | — | — | — |
| EV/EBITDA | 8.35 | 8.35 | — | — | — |
| P/B | 2.63 | 2.63 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 10.1% | 10.1% | 21.9% | 41.0% | — |
| EPS Growth | — | — | -1.7% | 58.8% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.05 → n/d
Residual
+2.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.